KORU Medical Systems, Inc. (KRMD)

KORU Medical Systems announced its First Quarter 2026 financial results on May 6, 2026, reporting a 22% increase in net revenues to $11.8 million over the prior year period, with gross profit growing 20% to $7.2 million and net loss improved by 31% to ($0.8) million. In March 2026, KORU Medical Systems announced receiving EU MDR Certification for its Freedom60® Infusion Pump, including compatibility with prefilled syringes, which is significant for its international expansion and a CEO transition was also announced. In November 2025, the company reported a 27% revenue growth for the Third Quarter 2025 and raised its full-year 2025 revenue guidance. The stock price as of April 20, 2026, was $4.26 per share, representing a 90.18% increase from $2.24 per share on April 21, 2025. Over the past 52 weeks, KRMD has traded between a low of $2.63 and a high of $6.61.

Information explicitly detailing demand seasonality for KORU Medical Systems, Inc.'s products and services was not found in the provided search results. The company's revenue streams include domestic core, international core, and pharma services and clinical trials, with domestic core being the majority. While some revenue streams like pharma services and clinical trials can be variable based on milestone and clinical trial timing, no overarching seasonal patterns for product demand were identified.

KORU Medical Systems, Inc. specializes in developing, manufacturing, and commercializing large volume subcutaneous infusion solutions, operating within the Healthcare sector, specifically in the Medical Instruments & Supplies and Health Care Equipment industries. Its core product line, FREEDOM Infusion Systems, delivers therapies for chronic illnesses like Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The company's revenue streams are categorized into Domestic Core, International Core, and Pharma services and clinical trials, with the majority of revenue derived from its Domestic Core business.

KORU Medical Systems primarily generates revenues from the United States, but also has an international core business and is expanding globally, particularly into prefilled syringe markets within the European Union. The company's headquarters are located in Mahwah, New Jersey, United States.

KORU Medical Systems focuses on being a leading developer and manufacturer of medical devices and supplies, emphasizing home and specialty infusion solutions. The company highlights responsive problem-solving for its customers and careful consideration for the patient experience. Its stated company values include customer commitment, collaboration ("One Koru"), operating with integrity, pursuit of excellence, celebrating the journey, and empowering and growing its people.

KORU Medical Systems, Inc. has a significant institutional ownership presence with 84 institutional owners and shareholders holding a total of 20,259,497 shares. Major institutional owners include First Light Asset Management, LLC, Topline Capital Management, LLC, BlackRock, Inc., Vanguard Group Inc, Geode Capital Management, Llc, Meros Investment Management, LP, Empire Financial Management Company, LLC, Simcoe Capital LLC, State Street Corp, and Morgan Stanley. Horton Capital Partners Fund, L.P. is also a notable holder. Institutional investors and hedge funds collectively own 58.60% of the stock, individual insiders hold 7.99% of the shares, while the general public holds 21.7%.